April Breyer Menon, Author at Venable's BiologicsHQ

Supreme Court Rejects Federal Circuit’s Basis for Finding Infringement Liability for U.S. Exporters Under § 271(f)(1): Life Technologies Corp. et al. v. Promega Corp.

by April Breyer Menon | Feb 22, 2017

The Supreme Court reversed the Federal Circuit’s interpretation of an infringement liability statute in litigation over whether shipping a single component of a patented multi-component invention to be assembled overseas qualifies as an infringing act under 35 U.S.C....

Federal Circuit Pushes Back on Procedural Issues

by April Breyer Menon | Feb 1, 2017

The Federal Circuit is not afraid to call to task the Patent Trial and Appeal Board when it comes to potential procedural breaches. Justin Oliver and Kathryn Easterling review relevant cases. Download PDF

Federal Circuit Dismisses Appeal By IPR Petitioner For Lack Of Article III Standing Due To Insufficient Evidence Of Injury To Petitioner Arising From Challenged Patent

by April Breyer Menon | Jan 9, 2017

The Court of Appeals for the Federal Circuit today held that, in order to appeal a final decision from an inter partes review (IPR) proceeding, an IPR petitioner must prove Article III standing, including an injury in fact—and moreover must do so by a burden of proof...

The Supreme Court Hears Oral Argument On Infringement Liability For U.S. Exporters Under § 271(f)(1): Life Technologies Corp., et al. v. Promega Corp.

by April Breyer Menon | Dec 7, 2016

On December 6, 2016, the Supreme Court heard oral argument on the interpretation and application of 35 U.S.C. § 271(f)(1) in Life Technologies Corp., et al. v. Promega Corp. At issue is whether the export from the United States of a single component of a patented...

Approval Biosimilar Notice Implicates Millions

by April Breyer Menon | Aug 3, 2016

Managing Intellectual Property Blog The Federal Circuit recently held that makers of biosimilars must always notify brand-name rivals six months before commercial product launch. Download PDF

« Older Entries

Next Entries »

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.